home / stock / kros / kros news

KROS News and Press, Keros Therapeutics Inc. From 08/05/21

Stock Information
Company Name: Keros Therapeutics Inc.
Stock Symbol: KROS
Market: NASDAQ
Website: kerostx.com
Menu
KROS KROS Quote KROS Short KROS News KROS Articles KROS Message Board
Get KROS Alerts

News, Short Squeeze, Breakout and More Instantly...
KROS - Keros Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results

LEXINGTON, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients sufferi...
KROS - Keros Therapeutics appoints Simon Cooper as CMO

Keros Therapeutics (KROS +3.8%) announces the appointment of Simon Cooper, M.B.B.S, as Keros' Chief Medical Officer, or CMO, effective as of August 2, 2021. Dr. Cooper most recently served as the Senior Vice President, Chief Medical Officer of Kadmon (NASDAQ:KDMN). Dr. Cooper is succeeding Cl...

KROS - Keros Therapeutics Appoints Simon Cooper, M.B.B.S. as Chief Medical Officer

LEXINGTON, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and muscu...

KROS - Bellerophon Therapeutics and Entera Bio among healthcare gainers; Second Sight Medical Products and Adial Pharmaceuticals among losers

Gainers: Entera Bio (ENTX) +56%. Orphazyme (ORPH) +47%. Bellerophon Therapeutics (BLPH) +26%. HUTCHMED (HCM) +11%. Evaxion Biotech (EVAX) +8%.Losers: Gemini Therapeutics (GMTX) -32%. Second Sight Medical Products (EYES) -19%. Millendo Therapeutics (MLND) -17...
KROS - Keros to extend phase 2 treatment duration of myelodysplastic syndromes candidate

tonaquatic/iStock via Getty Images Keros Therapeutics (KROS) says it will extend the phase 2 treatment duration of myelodysplastic syndromes ("MDS") candidate KER-050 from 12 weeks to up to two years to measure duration of response. Preliminary results released today indicated that as of...

KROS - Keros Therapeutics Announces Preliminary Results from its Phase 2 Clinical Trial Evaluating KER-050 in Patients with Myelodysplastic Syndromes

LEXINGTON, Mass., June 22, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and muscu...

KROS - Keros Therapeutics Presents Preclinical Data from ALK2 and KER-050 Hematology Programs at the European Hematology Association EHA2021 Virtual Congress

Multiple poster presentations demonstrate that ALK2 inhibition lowered hepcidin levels and improved iron homeostasis in preclinical models of anemia and iron overload. Poster presentation demonstrates that KER-050 had effects on multiple stages of erythroblast maturation (both...
KROS - Keros Therapeutics to Present at the Jefferies Virtual Healthcare Conference

LEXINGTON, Mass., May 27, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and muscul...

KROS - Keros issued U.S. patent for use of therapeutic proteins in treatment of musculoskeletal disorders

Keros Therapeutics (KROS) announces the issuance of U.S. patent for the use of therapeutic proteins in treatment of musculoskeletal disorders.The United States Patent and Trademark Office (“USPTO”) has issued the company U.S. Patent No. 11,013,785.The patent contains 2...

KROS - Keros Therapeutics Announces Issuance of U.S. Patent for Use of Therapeutic Proteins in Treatment of Musculoskeletal Disorders

LEXINGTON, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and muscul...
Previous 10 Next 10